XenTech’s technology is based on one of the world’s largest and best characterized collection of Patient-Derived primary tumor Xenograft models (PDX).
Our ambition is to foster therapeutic development in Oncology by offering an innovative translational platform, developing clinically relevant tumor models and addressing tomorrow’s needs in preclinical oncology research.
Commitment to scientific excellence
XenTech is a spin-off of the Institut Curie, France’s largest cancer research institute, where our scientists have conducted preclinical studies for over 15 years in collaboration with industrial and academic laboratories.
Our team ensures high quality research and ethical standards and is continuously working to keep up to date with new technologies.
Spin-off of Institut Curie, France’s largest cancer research institute
Privately owned company
Founded in 2006
World’s largest panel of breast cancer patient-derived xenografts
Business model : fee-for-service research contracts
XenTech is committed to promoting equality in all aspects of its business.
As an employer XenTech aspires to promote a working environment in which everyone is treated with dignity and respect :
Social charter (french)
Recruitment policy (french)
Anti-corruption charter (french)
Ethical charter (french)